231 related articles for article (PubMed ID: 29733910)
1. The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer.
Munir MT; Ponce C; Powell CA; Tarafdar K; Yanagita T; Choudhury M; Gollahon LS; Rahman SM
J Steroid Biochem Mol Biol; 2018 Oct; 183():1-9. PubMed ID: 29733910
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of 27-hydroxycholesterol in cancer development and progression: An update.
Abdalkareem Jasim S; Kzar HH; Haider Hamad M; Ahmad I; Al-Gazally ME; Ziyadullaev S; Sivaraman R; Abed Jawad M; Thaeer Hammid A; Oudaha KH; Karampoor S; Mirzaei R
Int Immunopharmacol; 2022 Sep; 110():109074. PubMed ID: 35978522
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol and breast cancer pathophysiology.
Nelson ER; Chang CY; McDonnell DP
Trends Endocrinol Metab; 2014 Dec; 25(12):649-55. PubMed ID: 25458418
[TBL] [Abstract][Full Text] [Related]
4. Bird's eye view analysis of in situ cholesterol metabolic pathways in breast cancer patients and its clinicopathological significance in their subtypes.
Kosaka S; Miyashita M; McNamala K; Nomura M; Shima H; Kawai M; Sato I; Harada-Shoji N; Ishida T; Choi MH; Sasano H
J Steroid Biochem Mol Biol; 2022 Jul; 221():106103. PubMed ID: 35367370
[TBL] [Abstract][Full Text] [Related]
5. Obesity, cholesterol metabolism, and breast cancer pathogenesis.
McDonnell DP; Park S; Goulet MT; Jasper J; Wardell SE; Chang CY; Norris JD; Guyton JR; Nelson ER
Cancer Res; 2014 Sep; 74(18):4976-82. PubMed ID: 25060521
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
7. Increased 27-hydroxycholesterol production during luteolysis may mediate the progressive decline in progesterone secretion.
Xu Y; Hutchison SM; Hernández-Ledezma JJ; Bogan RL
Mol Hum Reprod; 2018 Jan; 24(1):2-13. PubMed ID: 29177442
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol, Oxysterols and LXRs in Breast Cancer Pathophysiology.
Nazih H; Bard JM
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079340
[TBL] [Abstract][Full Text] [Related]
9. ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.
Luo M; Bao L; Chen Y; Xue Y; Wang Y; Zhang B; Wang C; Corley CD; McDonald JG; Kumar A; Xing C; Fang Y; Nelson ER; Wang JE; Wang Y; Luo W
Sci Adv; 2022 Jul; 8(28):eabn5295. PubMed ID: 35857506
[TBL] [Abstract][Full Text] [Related]
10. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.
Kimbung S; Chang CY; Bendahl PO; Dubois L; Thompson JW; McDonnell DP; Borgquist S
Endocr Relat Cancer; 2017 Jul; 24(7):339-349. PubMed ID: 28442559
[TBL] [Abstract][Full Text] [Related]
11. 27-Hydroxycholesterol, The Estrogen Receptor Modulator, Alters DNA Methylation in Breast Cancer.
Vini R; Rajavelu A; Sreeharshan S
Front Endocrinol (Lausanne); 2022; 13():783823. PubMed ID: 35360070
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of monocytes and epigenetic silencing of intratumoral CYP7B1 primarily contribute to the accumulation of 27-hydroxycholesterol in breast cancer.
Shi SZ; Lee EJ; Lin YJ; Chen L; Zheng HY; He XQ; Peng JY; Noonepalle SK; Shull AY; Pei FC; Deng LB; Tian XL; Deng KY; Shi H; Xin HB
Am J Cancer Res; 2019; 9(10):2194-2208. PubMed ID: 31720082
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
14. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Dalenc F; Iuliano L; Filleron T; Zerbinati C; Voisin M; Arellano C; Chatelut E; Marquet P; Samadi M; Roché H; Poirot M; Silvente-Poirot S
J Steroid Biochem Mol Biol; 2017 May; 169():210-218. PubMed ID: 27343991
[TBL] [Abstract][Full Text] [Related]
15. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer.
McDonnell DP; Chang CY; Nelson ER
Climacteric; 2014 Dec; 17 Suppl 2(0 2):60-5. PubMed ID: 25320023
[TBL] [Abstract][Full Text] [Related]
16. On the regulatory importance of 27-hydroxycholesterol in mouse liver.
Heverin M; Ali Z; Olin M; Tillander V; Joibari MM; Makoveichuk E; Leitersdorf E; Warner M; Olivercrona G; Gustafsson JÅ; Björkhem I
J Steroid Biochem Mol Biol; 2017 May; 169():10-21. PubMed ID: 26851362
[TBL] [Abstract][Full Text] [Related]
17. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.
Nelson ER; Wardell SE; Jasper JS; Park S; Suchindran S; Howe MK; Carver NJ; Pillai RV; Sullivan PM; Sondhi V; Umetani M; Geradts J; McDonnell DP
Science; 2013 Nov; 342(6162):1094-8. PubMed ID: 24288332
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
Katz TA; Huang Y; Davidson NE; Jankowitz RC
Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypes.
Xu J; Wang Z; Li S; Chen J; Zhang J; Jiang C; Zhao Z; Li J; Li Y; Li X
Brief Bioinform; 2018 Jan; 19(1):52-64. PubMed ID: 27742663
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer and (25R)-26-hydroxycholesterol.
Javitt NB
Steroids; 2015 Dec; 104():61-4. PubMed ID: 26299212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
